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ABSTRACT
ObjectiveToassesstheefficacyofnaftidrofurylcompared
with placebo in treating the symptoms of intermittent
claudication.
Design Meta-analysis based on individual patient data.
Data sources Medline, International Pharmaceutical
Abstracts, Embase, Science Citation Index, and the
Cochrane trial registers. Reference lists of retrieved
articles were checked. Authors and companies were
approached for additional information and individual
patient data.
Inclusion criteria Double blind, randomised controlled
trials in patients with intermittent claudication receiving
oral naftidrofuryl or placebo and with pain-free walking
distance as primary outcome.
Data collection Individual patient data were collected
from electronic data or from case report forms and
checked for integrity.
AnalysisAllrandomisedpatientswereanalysedfollowing
the intention to treat principle. Efficacy was assessed by
theratioofgeometricmeanoftherelativeimprovementin
pain-free walking distance after use of naftidrofuryl
compared with placebo. In the analysis of responders,
therapeutic success was defined as an improvement of
walking distance at baseline by at least 50%.
ResultsIn total, 1266 patients were randomised (1083 in
the main analysis). The ratio of relative improvement in
pain-free walking distance after use of naftidrofuryl
compared with placebo was 1.37 (95% confidence
interval1.27to1.49).Thedifferenceinresponseratewas
22.3%(95%confidenceinterval17.1%to27.6%)andthe
number needed to treat for relief of symptoms during six
months of treatment was 4.48 (95% confidence interval
3.62 to 5.85).
Conclusion This meta-analysis of individual patient data
provides evidence that naftidrofuryl has a clinically
meaningful effect compared with placebo in improving
walking distance in patients with intermittent
claudication.
INTRODUCTION
Peripheral arterial occlusive disease, with or without
symptoms, occurs in about 12% of adults in the
Western world and in over 20% of adults aged over
70.
1-6 The disease is also prevalent in developing
countries.
7-9
Intermittent claudication, a hallmark of sympto-
matic peripheral arterial occlusive disease, occurs in
about 25% of patients with peripheral arterial disease.
The symptoms are leg pain while walking leading to
importantphysicallimitations,andreductioninquality
of life. Patients with intermittent claudication are at
increased risk of cardiovascular morbidity and
mortality.
110-12 Prevalence and severity of the disease
increase with age and the presence of cardiovascular
risk factors, mainly smoking and diabetes.
1314
Treatmentforintermittentclaudicationaimstoslow
the progression of atherosclerosis, reduce cardio-
vascularandcerebrovascularmorbidityandmortality,
relieve symptoms (improvement of walking distance),
and improve quality of life.
Secondarypreventionofcardiovasculardiseaseisan
importantpartofthetreatmentplan.
15-20Improvement
ofsymptomscanbeachievedbysupervisedexercise,
21
smokingcessation,
22-27anddrugtreatment.Alongwith
their cardiovascular protective effect, statins improve
the distance walked.
17 In a recent Cochrane review
based on six randomised controlled trials, cilostazol
(100 mg twice daily), a phosphodiesterase inhibitor,
was moderately effective at improving walking dis-
tance in patients with intermittent claudication com-
pared with placebo.
28 For more than 30 years
vasoactivedrugshavebeenproposedforuseinpatients
with intermittent claudication to improve walking
distance, either the pain-free walking distance or the
maximum walking distance. Robust data on the
efficacy of most vasoactive drugs have been lacking.
29
Although these drugs have been well promoted, their
use has been controversial. Several meta-analyses of
this drug class were carried out
30-33 and concluded that
the effects of vasoactive drugs on the symptoms of
intermittent claudication were modest. Since this drug
class consists of products with heterogeneous mechan-
isms of action, differences in clinical efficacy are
possible.
In a systematic review based on published aggre-
gated data on vasoactive drugs, naftidrofuryl was
singled out as a potential candidate for further
research.
34 This drug has been marketed since 1968
1Heymans Institute of
Pharmacology, Ghent University,
Ghent, Belgium
2Department of Cardiovascular
Disease, University Hospital
Ghent, Belgium
3Department of Statistics,
Facultes Universitaires
Catholiques de Mons, Leuven
Academy, Mons, Belgium
Correspondence to: T De Backer
Department of Cardiovascular
Disease,UniversityHospitalGhent,
De Pintelaan 185, 9000 Ghent,
Belgium tine.debacker@Ugent.be
Cite this as: BMJ 2009;338:b603
doi:10.1136/bmj.b603
BMJ | ONLINE FIRST | bmj.com page 1 of 8on the basis of presumed vascular, antiplatelet, and
intracellular actions.
35 Numerous reviews on naftidro-
furyl have been published
36-42 and the drug is
mentioned in European and transatlantic
guidelines,
4344 but no final judgment on its efficacy
has been made by the modern approach of systematic
meta-analysis. In the one systematic review on
naftidrofuryl, five of six eligible randomised clinical
trials showed a significant, albeit modest, effect.
34
Owing to heterogeneity
45 among the study results,
however, the authors refrained from classic meta-
analysis of published aggregated data. These metho-
dologicalproblemscouldbeovercomeonlybyameta-
analysis of individual patient data. We carried out a
meta-analysis within the framework of the Cochrane
Collaboration to assess the feasibility of engaging in
headtoheadtrialswithcilastazol,orontopoftrialswith
statins.
We used individual patient data to determine the
efficacy and safetyoforal naftidrofuryl comparedwith
placeboinimprovingwalkingdistanceinpatientswith
intermittent claudication.
METHODS
We searched the Cochrane trials registers, Medline
(1966 onwards), Embase (1980 onwards), Science
Citation Index, and International Pharmaceutical
Abstracts for trials of oral naftidrofuryl for the
treatment of intermittent claudication, and we hand
searched journals and conference proceedings. Rele-
vantbibliographieswerecheckedandwecontactedthe
authors of identified trials and Merck Laboratories,
registration holder of naftidrofuryl, for any unpub-
lished data. No language restrictions were applied.
Selection criteria and validity assessment
We selected randomised placebo controlled clinical
trials of patients with intermittent claudication who
receivedoralnaftidrofuryl600mgdailyorplaceboand
that had pain-free walking distance as the primary
outcome, defined as the distance walked during a
standardisedexercisetestbeforetheonsetofpain.The
secondary outcome was the maximum walking dis-
tance.
We assessed the selected trials for quality of trial
performance and reporting. Internal validity was
assessed by checking for appropriateness of the
randomisation process, the double blinding process,
and the handling of dropouts and withdrawals by
intervention group.
46
We used three additional disease specific quality
criteria: sufficient reporting of variability of results
(disregarded when individual patient data were avail-
able), minimum sample size of 30 participants, and
minimum study duration of three months.
47
Extraction of individual patient data
The principal investigators and the marketing author-
isationholderofnaftidrofuryl(MerckDarmstadt)were
contacted for the original individual patient data. Data
from secondary databases were checked against the
original case report forms. All randomised patients
withacasereportformordatabaserecordwereentered
inthepooleddatabase(intentiontotreatprinciple).We
retrievedthosepatientslosttofollow-uporexcludedin
thepublishedperprotocolanalysesandincludedthem
in the database of individual patient data.
Quantitative data synthesis
The research team agreed a statistical analysis plan
conforming to regulatory guidelines.
48 Treatment
codes were unknown and only provided at the end of
the analysis process. The main analysis was based on
intentiontotreat,inwhichallrandomisedpatientswere
considered. To enable comparison with the published
results, for each trial we identified those patients
providing data in the original publication, whether
theyhadcompletedthestudyandbeencompliantwith
the regimen (per protocol) or had at least one value
after baseline (restricted intention to treat).
Wecarriedoutanexploratorystepwiseregressionof
final walking distance to determine adjustment for
covariables. In this model, baseline walking distance
was singled out as the essential mediator of all other
baseline variables. Hence the model using individual
patientdata was adjustedfor baselinewalkingdistance
only.
For missing data on main end points we attributed
the worst case value in patients for whom the trial was
interrupted early for reasons related to peripheral
arterial occlusive disease (aggravation, admission to
hospital, or surgery). In all other randomised patients
for whom the trial was interrupted early, we used the
last observation carried forward. For the purposes of
sensitivity assessment, we carried out an alternative
analysis using summary statistics when at least two
intermediate post-baseline observations were avail-
able.
Potentially relevant randomised controlled trials
identified and screened for retrieval (n=67)
Retrieved for more detailed evaluation (n=11)
Failed to correspond to PICO criteria* (n=56)
Potentially appropriate for meta-analysis (n=7)
Excluded owing to flaws in quality, no covariables,
incomplete individual patient data (n=4)
Included in meta-analysis (n=7)
Excluded on basis of individual patient data (n=0)
Trials with usable information, by outcome (n=7)
Withdrawn, by outcome (n=0)
Flow of papers through trial. *Patients with intermittent
claudication (Fontaine stage II), intervention oral naftidrofuryl,
comparator oral placebo, and outcome walking distance
measured by standardised test
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random and then imputed data using a systematic full
information maximum likelihood technique.
49 The
main end point for each patient was the relative
improvement in pain-free walking distance—that is,
the final pain-free walking distance divided by the
baselinepain-freewalkingdistance.Forallparticipants
we used the geometric mean percentage of change
from baseline, with 95% confidence intervals. We
measured the treatment effect using the ratio of the
relative improvement in pain-free walking distance
after use of naftidrofuryl compared with placebo. A
similar approach was used for the secondary outcome
of maximal walking distance, for trials in which this
outcome was available.
Effectwasalsoexpressedinananalysisofresponders
—those patients whose pain-free walking distance
improvedbyatleast50%frombaseline.Wecalculated
the difference in success rates between naftidrofuryl
and placebo, the number needed to treat, the relative
benefit, and the odds ratio.
We carried out analyses using one stage and two
stage approaches. In the one stage approach the
database is considered as one dataset. In the two stage
approach the aggregated results of each study are
pooled and then analysed.
50
In the one stage approach for relative improvement
we used the multilevel (patient level and trial level)
general linear mixed model allowing analysis of
covariance
51 by considering random treatment effects
and fixed study effects and adjusting for baseline
walking distance. In the two stage approach we
calculatedaggregateestimatesofrelativeimprovement
foreachtreatmentgroupwithineachstudy,thenuseda
conventional random model of DerSimonian and
Laird.
52
In the one stage approachfor the responderanalysis
we used the mixed model for binary data
53 and for the
two stage approach we used the random model of
DerSimonian and Laird.
52
We set the α level of error for significance of the
treatment effect at 0.01. The confidence intervals were
presented at the 95% level. We tested stability of the
results using all trials, excluding and including
debatable trials, by comparing the results of full
intention to treat with restricted intention to treat and
per protocol analysis and by comparing the last
observation carried forward with missing data alloca-
tion based on summary statistics.
Safety
We assessed the safety of oral naftidrofuryl by
reviewing the reports of adverse drug reactions in the
randomised controlled clinical trials, by retrieving
published case reports, and by analysing the latest
periodic reports on safety from Merck Laboratories.
RESULTS
Of the studies retrieved, 11 randomised controlled
trials conformed to the PICO criteria (participants,
intervention, comparator, and outcome) and were
selected (table 1). Four trials were excluded after
quality assessment because of problems with internal
validity
w1 w2 w4 or absence of both good quality indivi-
dual patient data and covariables.
w1-w4 Two trials had
design flaws.
w1 w4 Individual patient data were not
available for the other two studies.
w2 w3 Covariables
were completely or partially absent in these four
trials.
w1-w4 Seven studies were included in the analysis
(table 2 and figure).
w5-w11
In a previous meta-analysis based on published
aggregate data
34 one study
w9 was excluded because it
showed no data on variability of the results. That
problem was solved here by using individual patient
data. The study also had poor internal validity, and
over 70% of the patients had a baseline pain-free
Table 1 |Assessment of trial quality and availability of individual patient data in trials included in meta-analysis of naftidrofuryl compared with placebo for
treatment of intermittent claudication
References
Disease specific criteria* Generalcriteriaforinternal
validity
Individual patient data Overall quality
grade‡ Sample size Duration Variability† Outcome Covariables
Excluded studies:
Ruckley et al 1978
w1 0 1 2 2 Incomplete Not available C
Pohle et al 1979
w2 1 1 0 1 Incomplete Not available C
Clyne et al 1980
w3 0 0 0 1 Incomplete Not available C
Karnik et al 1988
w4 1 1 2 2 Incomplete Not available C
Included studies:
Maass et al 1984
w5 0 1 0 1 Available Available B
Adhoute et al 1990
w6 0 0 0 1 Available Available B
Kriessman and Neiss
1988
w7
0 1 0 1 Available Available B
Adhoute et al 1990
w8 0 0 0 1 Available Available B
Moody et al 1994
w9 0 0 2 2 Available Available B
Boccalon et al 2001
w10 0 0 1 0 Available Available B
Kieffer et al 2001
w11 0 0 1 0 Available Available B
*Flaws: 0, none; 1, minor; 2, major.
†Risk of bias: grade A, no or low risk; grade B, moderate risk; and grade C, high risk.
‡No or incomplete reporting of variability is a major flaw but was disregarded in evaluation when individual patient data were available.
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study was classified as supportive, disregarded in the
mainanalysisofindividualpatientdata,butconsidered
in a sensitivity analysis.
Anotherstudy
w10wasofgoodquality,exceptthatthe
variability of the results was not well reported, which
again could be corrected by using individual patient
data. That study, however, used a non-conventional
method for measuring walking distance (peripheral
arterial disease holter control or PADHOC). This
method is claimed to represent a more physiological
walkingdistancebutresultsinhigherbaselineandfinal
values for walking distance. The trial was included but
the data were expressed as relative improvement and
not in absolute terms (metres gained). In addition, the
impact of this trial was evaluated in the sensitivity
analysis.
The integrity of the data collected from secondary
databases was randomly checked against the original
case report forms (www.sqconline.com/mil-std-105.
html), providing an estimate of at least 99% for data
reliability. Those patients who contributed to the
original published analyses were identified from the
databasebyusingtheindividualpatientdata(restricted
intention to treat
w9-w11 and per protocol
w5-w8). These
dataenabledconfirmationoftheconcordancebetween
the results of this subset in our database and the
published results.
Sixty five patients had only one baseline value for
pain-free walking distance, 189 for whom the trial was
interruptedhadatleastonevalueforwalkingdistance,
and 1012 completed the trial and had data at each
follow-up.However, in keepingwith a full intention to
treat analysis all patients lost to follow-up were
included. A last observed carried forward strategy
was used, and sensitivity analysis was carried out by
comparingwithresultsbasedontwoothermissingdata
allocation techniques (summary statistics and mixed
model analysis).
Overall, 7.8% of covariables were found to be
missing at random and were allocated by a full
information maximum likelihood procedure. Data
were missing for smoking (n=11), systolic blood
pressure (n=10), diabetes (n=15), hyperlipidaemia
(n=12), exercise or sedentary lifestyle (n=9), angina
pectoris(n=11),height(n=2),andweight(n=1).Missing
datawereuniformlydistributedacrossallvariablesand
casesandwereconsideredasmissingatrandomcheck.
Publication bias
Formal checks for publication bias were problematic
because of the small variation in sample size of the
studies, ranging from 142 to 235. In statistical terms
publication bias would need to be interpreted by the
square root of the sample size (11.9, 15.3), which is a
smallrange.Hence,funnelplotsbasedondetectionofa
positive monotonic relation between efficacy and
sample size are of limited relevance.
Notracestounpublishedstudieswerefound,despite
a search of trial registers and the reference lists of
relevant articles (snowballing).
Study characteristics
In total, 1266 patients (626 placebo, 640 naftidrofuryl)
from seven studies constituted the individual patient
datain thedatabase:Maasset al(n=142),
w5Adhouteet
al (146)
w6 Kriessman and Neiss (235),
w7 Adhoute et al
(182),
w8 Moody et al (183),
w9 Boccalon et al (182),
w10
and Kieffer et al (196).
w11 Table 3 summarises the
characteristics of the sample.
Themeanageofthepatientswas62.41yearsandthe
bodymassindexwas24.92.Theyhadmildlyincreased
systolic blood pressures (148.96 mm Hg) and as
expected they had a decreased ankle brachial index,
of0.65.Justoveronesixthofthepatientswerewomen.
About50%weresmokers,56%hadhypertension,13%
had diabetes, 38% had hyperlipidaemia, 43% had a
sedentary lifestyle, and 11% had angina.
Therewasheterogeneitybetweenstudiesbutthetwo
treatmentarmswerewellmatchedforbaselinewalking
distance (geometric mean 140.62 m for naftidrofuryl v
140.26 m for placebo) and for covariables within each
studyaswellasinthefullset.Stepwiselinearregression
of the final walking distance as a dependent variable
revealed that baseline walking distance was the key
predictor (R
2=0.479), not the covariables.
Intotal,896patients(71%)haddataavailableforthe
finalassessment,305(24%)hadatleastoneassessment
afterbaseline,and65(5%)hadnooutcomedata,onlya
randomisation code.
Table 2 |Sample size, duration of trials, dosages of naftidrofuryl or placebo, and aspirin use in studies included in meta-analysis on efficacy of naftidrofuryl
compared with placebo for treatment of intermittent claudication
Studies
Sample size
Duration (months) Drug dosage (naftidrofuryl or placebo) No (%) using aspirin Individual patient data* Per protocol
Maass et al
w5 142 104 3 200 mg three times daily 94 (66)
Adhoute et al
w6 146 118 6 200 mg three times daily 88 (60)
Kriessman and Neiss
w7 235 136 3 316.5 mg twice daily 31 (78)†
Adhoute et al
w8 182 94 6 316.5 mg twice daily 109 (60)
Moody et al
w9 183 170 6 316.5 mg twice daily 115 (63)
Boccalon et al
w10 182 122 12 200 mg three times daily 117 (65)
Kieffer et al
w11 196 152 8 200 mg three times daily 127 (65)
All
w5-w11 1266 896 6.3 — 681 (64)
*Intention to treat.
†Accurate data were available for 1071 patients; study by Kriessmann and Neiss
w7 had reliable data on aspirin use in only 40 patients (data were missing for 195 patients).
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The main analysis was carried out on an intention to
treatbasisonallpatientsinthesixtrials(1083patients).
One study, by Moody et al,
w9 was excluded.
In the one stage approach the relative improvement
in pain-free walking distance after use of naftidrofuryl
compared with placebo was 1.37 (95% confidence
interval 1.27 to 1.49; P<0.001). The analysis of
responders (table 4) showed that 30.2% responded to
placebo and 54.7% to naftidrofuryl. The absolute
difference in response rate was 22.3% (17.1% to
27.6%). The number needed to treat was 4.48 (95%
confidence interval 3.62 to 5.85).
Intheanalysisofthesecondaryoutcome,maximum
walking distance was not measured in all studies, and
onlyinasubsetofpatientsinsome(n=968,sixstudies).
The relative improvement in maximum walking
distance was 1.40 (95% confidence interval 1.19 to
1.63),andtheabsolutedifferenceinresponserateswas
23.9% (15.7% to 32.1%).
Theestimatesfortreatmenteffectusingtheonestage
approachweremoreconservativethanthoseusingthe
two stage approach, but more precise (tighter con-
fidence intervals, table 4).
Inthetwostageapproachtheheterogeneitybetween
studies was significant (P=0.001). Baseline handicap
did not, however, significantly affect the difference in
relative improvement (mixed model, P>0.05), which
remained constant for both treatment arms except for
the larger initial walking distance, where the placebo
effect seemed to decrease. Heterogeneity
45 was taken
into account in the one stage approach by multilevel
techniques and in the two stage approach by the
random model of DerSimonian and Laird.
Inthesensitivityanalysis(table 5)theadditionofthe
study by Moody et al
w9 resulted in a relative improve-
ment after use of naftidrofuryl compared with placebo
of 1.37 (95% confidence interval 1.28 to 1.48). When
the study by Boccalon et al
w10 was eliminated the ratio
was 1.31 (1.24 to 1.39). For the per protocol sample
(n=726) the value was 1.42 (1.22 to 1.65). The ratio for
thelastobservationcarriedforwardcomparedwiththe
summary statistics was 1.37 (1.28 to 1.48) for nafti-
drofurylcomparedwith1.52(1.44to1.62)forplacebo.
These results all remained statistically significant.
A sensitivity analysis on the impact of the four
excludedtrials,
w1-w4basedoneffectsizes,indicatedthat
their inclusion would have a neutral to inflating effect
on the results, without changing the direction of the
conclusions.
Safety
No serious drug related events or fatalities were
reported in the reports of the clinical trials. The few
published case reports on adverse effects of oral
naftidrofurylpertaintoliverinjury,
54-56calciumoxalate
crystalluria with evolution to lithiasis,
5758 and severe
rhythm and conduction abnormalities due to massive
poisoning.
59 A larger number of published cases of
severe events relate to the historical parenteral use of
naftidrofuryl.
In the latest safety update from Merck Laboratories,
the maximum incidence at 95% confidence of drug
Table 3 |Samples’ characteristics by trial arm of studies on efficacy of naftidrofuryl compared with placebo for treatment of
intermittent claudication. Values are numbers (percentages) of patients unless specified otherwise
Variables Overall (n=1266) Naftidrofuryl (n=640) Placebo (n=626)
Mean (SD) age (years) 62.41 (9.48) 62.45 (9.39) 62.36 (9.58)
Mean (SD) body mass index 24.92 (3.26) 24.93 (3.57) 24.92 (2.91)
Mean (SD) systolic blood pressure (mm Hg) 148.96 (20.92) 148.63 (20.67) 149.3 (21.18)
Mean (SD) ankle brachial index 0.65 (0.17) 0.64 (0.17) 0.64 (0.17)
Mean(SD) durationofperipheralarterialdisease (years) 3.35 (3.41) 3.42 (3.52) 3.29 (3.3)
Geometric mean (95% CI) walking distance (m) 140.44 (135.00 to 146.11) 140.62 (133.07 to 148.61) 140.26 (132.52 to 148.45)
Women 222 (17.5) 121 (18.9) 101 (16.1)
Obesity 592 (46.8) 295 (46.1) 297 (47.4)
Current smoker 630 (49.8) 331 (51.7) 299 (47.8)
Hypertension 710 (56.1) 372 (58.1) 338 (54)
Type 2 diabetes 170 (13.4) 96 (15) 74 (11.8)
Hyperlipidaemia 486 (38.4) 242 (37.8) 244 (39)
Sedentary 541 (42.7) 278 (43.4) 262 (41.9)
Angina 142 (11.2) 82 (12.8) 60 (9.6)
Table 4 |Efficacy estimates in main analysis (n=1083) of meta-analysis using individual patient
data on efficacy of naftidrofuryl compared with placebo for treatment of intermittent
claudication
Relative improvement analysis One stage approach Two stage approach
Ratioofrelativeimprovementinpain-
free walking distance (95% CI)*
1.37 (1.27 to 1.49) 1.38 (1.24 to 1.56)
Ratio of relative improvement in
maximal walking distance (95% CI)†
1.40 (1.19 to 1.63) 1.38 (1.18 to 1.61)
Responder analysis:
Absolute difference in response
rates (95% CI)
22.3 (17.1 to 27.6) 24.8 (12.2 to 37.4)
Number needed to treat (95% CI) 4.48 (3.62 to 5.85) 4.03 (2.51 to 8.19)
Relative benefit (95% CI) 1.75 (1.50 to 2.03) 1.84 (1.36 to 2.45)
Odds ratio (95% CI) 2.65 (2.10 to 3.37) 2.90 (1.70 to 4.94)
*Ratio of final pain-free walking distance over baseline pain-free walking distance after use of naftidrofuryl
compared with placebo.
†Ratio of final maximal walking distance over baseline maximal walking distance after use of naftidrofuryl
compared with placebo.
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per 100000 patient treatment years. These events
essentially consisted of gastric disorders, with an
absolute difference in risk of 2.85% (0.78% to 4.91%)
comparedwithplaceboandrelativeriskof1.75(1.25to
2.45).Nootherspecificorgandisorderwasofclinically
relevant incidence. A limited number of neurological,
cardiovascular, and skin adverse reactions were
reported, but their incidence was no different than
with placebo.
DISCUSSION
In patients with intermittent claudication behavioural
and pharmacological measures to modify the cardio-
vascular risk profile are of prime importance. Sympto-
matictreatmentbyimprovingthewalkingdistancecan
have a clinically relevant impact on functional
capability and quality of life. This can be achieved by
behavioural measures (exercise and smoking cessa-
tion) as well as drug treatment.
Evidence on the efficacy of drugsto achieve relief of
symptoms in intermittent claudication is available for
statins and cilostazol. This review using individual
patient data provides statistical evidence that naftidro-
furyl,pickedoutofthecontroversialclassofvasoactive
drugs, has a moderate clinically meaningful effect by
improving walking distance in patients with inter-
mittentclaudication.Patientsinthenaftidrofurylgroup
walked37%furtherthanpatientsintheplacebogroup.
The number of patients responding to naftidrofuryl
(improvementbymorethan50%)was22%higherthan
the number responding to placebo. Once superiority
overplaceboisproved,thewayisopenforheadtohead
trials with active drugs for symptomatic treatment of
intermittent claudication.
Quality of life measures may add robustness to the
efficacy data.
6061 The tolerance and safety profiles of
oral naftidrofuryl are acceptable. The current market
pricefornaftidrofurylatadosageof200mgthreetimes
daily is €1( £0.90; $1.26).
The use of oral naftidrofuryl to treat intermittent
claudication could be recommended in patients who
still have symptoms after maximal secondary preven-
tion measures, including exercise therapy (if feasible),
or after revascularisation (if indicated), with re-evalua-
tion after three to six months. Within the indication of
symptomatic treatment, its use should be evaluated
against cilostazol and statins.
The authors believe that the results of this meta-
analysis on the efficacy of naftidrofuryl using indivi-
dual patient data can be trusted. Access to the data,
however, depended on the goodwill of Merck Darm-
stadt, the marketing authorisation holder. We found
references and full text of identified studies in the
medical literature, but for individual patient data we
hadtorelyonthepermissionofMerckLaboratories,as
data were not readily available from the principal
investigators. The company, who funded most of the
studies in this review, provided the data without
preliminary conditions. The meta-analysis was funded
by our university and not by Merck Laboratories, as
directed by the Cochrane Collaboration. The data
werecriticallyverifiedandanalysed.Despitecheckson
the integrity of the data some uncertainty remains
about the authenticity of the original data, as some
studies date from before the period when rigorous
checks for good clinical practice were implemented.
However our comparison of the per protocol and
restrictedintentiontotreatdatainourdatabasewiththe
published results were reassuring.
In this study we exploited several advantages of
using individual patient data: standardisation of out-
come choice (pain-free walking distance), standardisa-
tion of expressing the outcome (geometric mean of
relativeimprovement)acrossallstudies,applicationof
powerful analytical methods taking into account
heterogeneity, and full intention to treat analysis.
We found that it is difficult but not impossible to
collect data from randomised clinical trials and
individual patients, even for older products with
studies done decades ago. For newly developed
medicines,however,sharedownershiporunrestricted
access to individual patient data from drug related
randomisedcontrolledtrialsshouldbepossibleforthe
principal investigators of the trials, legal statistical
supervisors, regulatory authorities, and researchers
producing evidence based summaries of existing
knowledge, with due consideration of patient privacy.
This paper is based on a Cochrane review published in the Cochrane
Library on 16 April, issue 2, 2008.
Contributors: TDeB contributed to the planning, literature search, data
collection, quality assessment of the studies, data extraction, data
Table 5 |Sensitivity analysis (one stage approach) using individual patient data on efficacy of
naftidrofuryl compared with placebo for treatment of intermittent claudication
Analysis Sample size Mean relative improvement* (95% CI)
Main analysis (all studies minus Moody
et al
w9)
1083 1.37 (1.27 to 1.48)
Sensitivity analysis:
All studies
w5-w11 1266 1.37 (1.28 to 1.48)
All studies minus Boccalon et al
w10 1084 1.31 (1.24 to 1.39)
All studies minus Moody et al
w9 and
Boccalon et al
w10
901 1.32 (1.24 to 1.40)
Per protocol 726 1.42 (1.22 to 1.65)
*Relative improvement in pain-free walking distance after use of naftidrofuryl compared with placebo.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Exercise training and statins have proved beneficial in the symptomatic treatment of
intermittent claudication
Theuse ofvasoactivedrugs hasalwaysbeencontroversialbecauseofpoorand unconfirmed
evidence of clinical efficacy
WHAT THIS STUDY ADDS
Naftidrofurylismoderatelyeffectiveatimprovingwalkingdistanceinpatientswithintermittent
claudication
Head to head trials with cilostazol and on top of trials with statins can now be done with
assessment of ratio of benefit to risk, quality of life, and cost effectiveness
Older products should undergo a thorough review of their ratio of benefit to risk
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